Deferoxamine (Desferal)-induced ocular toxicity.

A 4-year-old girl with juvenile chronic myeloid leukemia relapsed after an allogeneic bone marrow transplantation (BMT) and became refractory to conventional chemotherapy. Treatment with two courses of high-dose deferoxamine, an iron chelator (130-180 mg/kg/day), along with low-dose ARA-c (5 mg/kg/day) caused a remarkable decrease of the WBC and fetal Hb. Three days following the last dose of deferoxamine, the patient experienced an acute visual loss, confirmed by electroretinogram (ERG) and visual evoked response (VER). Slight improvement occurred a few days later, but the patient developed severe pancytopenia and died of Klebsiella septic shock. The ocular manifestations were attributed to deferoxamine toxicity in light of the rapid onset after first exposure, the electrophysiological pattern of metabolic damage in the ERG and VER, and the long interval between the last chemotherapy and BMT. The pathogenesis of deferoxamine toxicity is discussed.

[1]  Z. Estrov,et al.  Effect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells. , 1987, Leukemia.

[2]  Z. Estrov,et al.  In vitro and in vivo effects of deferoxamine in neonatal acute leukemia , 1987 .

[3]  N. Monnier,et al.  Toxicité oculaire sévère de la desferrioxamine chez l'hémodialysé , 1987 .

[4]  E. Chew,et al.  Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. , 1986, The New England journal of medicine.

[5]  J. Lunec,et al.  Cerebral and ocular toxicity induced by desferrioxamine. , 1985, The Quarterly journal of medicine.

[6]  R. Orton,et al.  Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy. , 1985, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[7]  C. L. White,et al.  Neurologic complications of bone marrow transplantation , 1985, Neurology.

[8]  M. Freedman,et al.  Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. , 1984, Blood.

[9]  V. Lakhanpal,et al.  Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. , 1984, Ophthalmology.

[10]  C. Borgna-Pignatti,et al.  VISUAL LOSS IN PATIENT ON HIGH-DOSE SUBCUTANEOUS DESFERRIOXAMINE , 1984, The Lancet.

[11]  G. Arden,et al.  OCULAR TOXICITY OF HIGH-DOSE INTRAVENOUS DESFERRIOXAMINE , 1983, The Lancet.

[12]  P. Dieppe,et al.  Effect of a specific iron chelating agent on animal models of inflammation. , 1983, Annals of the rheumatic diseases.

[13]  S. Fliesler,et al.  Chemistry and metabolism of lipids in the vertebrate retina. , 1983, Progress in lipid research.

[14]  T. Ushio,et al.  CORTICAL BLINDNESS IN A CHILD WITH ACUTE LEUKEMIA , 1980, Acta paediatrica Scandinavica.

[15]  S. Sherlock,et al.  Acute renal insufficiency occurring during intravenous desferrioxamine therapy. , 2009, Scandinavian journal of haematology.

[16]  B. Modell.  Advances in the use of iron-chelating agents for the treatment of iron overload. , 1979, Progress in hematology.

[17]  A. Markenson,et al.  Lens opacities in thalassemia. , 1978, Journal of pediatric ophthalmology and strabismus.

[18]  J. Graziano,et al.  Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine. , 1978, The Journal of pediatrics.

[19]  N. Jaffe,et al.  Leukemic ophthalmopathy in children , 1976, Cancer.

[20]  Smith Rs.  Iron Excretion in Thalassaemia Major After Administration of Chelating Agents , 1962 .